Suven Life Sciences, a biopharmaceutical and contract research and manufacturing company has granted an exclusive license and right to distribute and market its Malathion Lotion USP 0.5 per cent w/v with US Patent # 8,138,366 and ANDA 091559 in the US, Canada and Mexico to Taro Pharmaceuticals North America, a subsidiary of Taro Pharmaceutical Industries.
Malathion lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair. In consideration for the exclusive license and right to distribute and market Malathion Lotion 0.5 per cent w/v USP in North America, Taro will pay Suven a royalty and the arrangement is effective until April 2028 unless otherwise terminated.
EP News Bureau – Mumbai